Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-label Study of Tenalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia
2019-003622-25Phase 2Completed
- Sponsor
- Rhizen Pharmaceuticals AG
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tenalisib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Rhizen Pharmaceuticals AG. Primary endpoint: Anti-tumor activity of Tenalisib. Started Oct 2019; status: completed.
02
Drugs
tenalisib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2019-003622-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003622-25.